SoftOx pivots clinical focus to chronic lung disease treatment

SoftOx Solutions AS (OSL:SOFTX) is refining its clinical focus towards chronic lung diseases, specifically initiating a proof-of-concept (POC) study for SoftOx Inhalation Solution (SIS) in people with cystic fibrosis. This strategic shift, evaluated by external experts, will assess SIS's safety across escalating doses and its effects on pulmonary bacterial load, establishing a foundation for future clinical advancements in chronic indications like non-cystic fibrosis bronchiectasis and acute indications such as ventilator-associated pneumonia.

The POC trial will begin in Q1 2026, with dose escalation readouts expected in H1 2026 and the study concluded in Q1 2027. It will require a €7-8 million investment. An investor update regarding this refinement will be presented by chairman of the board Ulrik Spork and chief executive Thomas Bjarnsholt on Monday, September 8, at 10:00 AM. The presentation will be recorded and made available afterward.

This refocused approach aims to leverage SIS's pan-antimicrobial properties across a broader spectrum of lung infections. The addressable market for SIS in CF is estimated to be above $600 million, while for NCFB, it could reach ~$5 billion. The company believes positive data from this trial will make SIS an attractive partnering candidate for global pharmaceutical companies.